Similar articles for PMID: 15872360

Year	Number of Results
1954	1
1959	2
1960	3
1961	2
1962	3
1973	1
1974	1
1976	1
1977	1
1982	1
1985	1
1988	3
1989	3
1990	3
1991	2
1992	1
1994	3
1995	5
1996	5
1997	6
1998	3
1999	11
2000	7
2001	5
2002	9
2003	9
2004	7
2005	16
2006	5
2007	2
2008	3
2009	1
2010	3
2011	2
2012	5
2013	2
2014	2
2015	2
2016	3
2017	2
2018	3
2019	2
2020	2
2021	1
2022	1
2023	1
2024	0

1

Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen.

Vallabhajosula S, Goldsmith SJ, Hamacher KA, Kostakoglu L, Konishi S, Milowski MI, Nanus DM, Bander NH. Vallabhajosula S, et al. J Nucl Med. 2005 May;46(5):850-8. J Nucl Med. 2005. PMID: 15872360 Free article. Clinical Trial.

2

Radioimmunotherapy of prostate cancer using 90Y- and 177Lu-labeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicity.

Vallabhajosula S, Goldsmith SJ, Kostakoglu L, Milowsky MI, Nanus DM, Bander NH. Vallabhajosula S, et al. Clin Cancer Res. 2005 Oct 1;11(19 Pt 2):7195s-7200s. doi: 10.1158/1078-0432.CCR-1004-0023. Clin Cancer Res. 2005. PMID: 16203821 Clinical Trial.

3

Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu?

Vallabhajosula S, Kuji I, Hamacher KA, Konishi S, Kostakoglu L, Kothari PA, Milowski MI, Nanus DM, Bander NH, Goldsmith SJ. Vallabhajosula S, et al. J Nucl Med. 2005 Apr;46(4):634-41. J Nucl Med. 2005. PMID: 15809486 Free article. Clinical Trial.

4

Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.

Rosenblum MG, Verschraegen CF, Murray JL, Kudelka AP, Gano J, Cheung L, Kavanagh JJ. Rosenblum MG, et al. Clin Cancer Res. 1999 May;5(5):953-61. Clin Cancer Res. 1999. PMID: 10353726 Clinical Trial.

5

High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.

Behr TM, Béhé M, Stabin MG, Wehrmann E, Apostolidis C, Molinet R, Strutz F, Fayyazi A, Wieland E, Gratz S, Koch L, Goldenberg DM, Becker W. Behr TM, et al. Cancer Res. 1999 Jun 1;59(11):2635-43. Cancer Res. 1999. PMID: 10363986

6

A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.

Wong JYC, Chu DZ, Yamauchi DM, Williams LE, Liu A, Wilczynski S, Wu AM, Shively JE, Doroshow JH, Raubitschek AA. Wong JYC, et al. Clin Cancer Res. 2000 Oct;6(10):3855-63. Clin Cancer Res. 2000. PMID: 11051230 Clinical Trial.

7

Improved prediction of myelotoxicity using a patient-specific imaging dose estimate for non-marrow-targeting (90)Y-antibody therapy.

Shen S, Meredith RF, Duan J, Macey DJ, Khazaeli MB, Robert F, LoBuglio AF. Shen S, et al. J Nucl Med. 2002 Sep;43(9):1245-53. J Nucl Med. 2002. PMID: 12215566 Free article. Clinical Trial.

8

Phase I therapy study of 186Re-labeled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck.

Colnot DR, Quak JJ, Roos JC, van Lingen A, Wilhelm AJ, van Kamp GJ, Huijgens PC, Snow GB, van Dongen GA. Colnot DR, et al. J Nucl Med. 2000 Dec;41(12):1999-2010. J Nucl Med. 2000. PMID: 11138685 Free article. Clinical Trial.

9

Dosimetric analysis of 177Lu-cG250 radioimmunotherapy in renal cell carcinoma patients: correlation with myelotoxicity and pretherapeutic absorbed dose predictions based on 111In-cG250 imaging.

Stillebroer AB, Zegers CM, Boerman OC, Oosterwijk E, Mulders PF, O'Donoghue JA, Visser EP, Oyen WJ. Stillebroer AB, et al. J Nucl Med. 2012 Jan;53(1):82-9. doi: 10.2967/jnumed.111.094896. Epub 2011 Dec 12. J Nucl Med. 2012. PMID: 22159179 Free article. Clinical Trial.

10

A stylized computational model of the rat for organ dosimetry in support of preclinical evaluations of peptide receptor radionuclide therapy with (90)Y, (111)In, or (177)Lu.

Konijnenberg MW, Bijster M, Krenning EP, De Jong M. Konijnenberg MW, et al. J Nucl Med. 2004 Jul;45(7):1260-9. J Nucl Med. 2004. PMID: 15235075 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

151 results

Results by year